Rizzo Daniel J
Known title: EVP, Sales, Consulting, & SvcsCIK: 0002154448
Associated companies
Transaction History
| VEEV | ▼ Sell | Open Market | 4,520 | $1.2M | 10/2/2026 | View on chart |
| VEEV | ▼ Sell | Open Market | 321 | $89K | 10/2/2026 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,672 | $0 | 10/1/2026 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 854 | $241K | 10/1/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus
Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.